AMPH
Amphastar Pharmaceuticals, Inc. Healthcare - Drug Manufacturers - Specialty & Generic Investor Relations →
Amphastar Pharmaceuticals, Inc. (AMPH) closed at $19.50 as of 2026-03-20, trading 47.9% below its 200-week moving average of $37.42. This places AMPH in the extreme value zone. The stock moved further from the line this week, up from -51.5% last week. The 14-week RSI sits at 36, indicating neutral momentum.
A big jump in activity this week — 2.1x the usual volume, and the price went up. Significantly more people than usual decided to buy. This kind of surge, especially on a stock already below its 200-week average, can be an early sign that sentiment is shifting.
Over the past 564 weeks of data, AMPH has crossed below its 200-week moving average 14 times. On average, these episodes lasted 10 weeks. Historically, investors who bought AMPH at the start of these episodes saw an average one-year return of +42.2%.
With a market cap of $896 million, AMPH is a small-cap stock. The company generates a free cash flow yield of 9.1%, which is notably high. Return on equity stands at 12.9%. The stock trades at 1.1x book value.
The company has been aggressively buying back shares, reducing its share count by 5.1% over the past three years. This stock also meets the Yartseva multibagger criteria as a small-cap with strong free cash flow yield and reasonable book value.
Over the past 10.8 years, a hypothetical investment of $100 in AMPH would have grown to $113, compared to $379 for the S&P 500. AMPH has returned 1.1% annualized vs 13.1% for the index, underperforming the broader market over this period.
Free cash flow has been growing at a 22.2% compound annual rate, with 4 consecutive years of positive cash generation. A business generating more cash every year while trading below its 200-week moving average is exactly the kind of disconnect value investors look for.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: AMPH vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After AMPH Crosses Below the Line?
Across 14 historical episodes, buying AMPH when it crossed below its 200-week moving average produced an average return of +30.3% after 12 months (median +34.0%), compared to +13.1% for the S&P 500 over the same periods. 86% of those episodes were profitable after one year. After 24 months, the average return was +73.6% vs +22.2% for the index.
Each line shows $100 invested at the moment AMPH crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
AMPH has crossed below its 200-week MA 14 times with an average 1-year return of +42.2% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Sep 2015 | Nov 2015 | 6 | 12.3% | +76.1% | +71.1% |
| Jan 2016 | May 2016 | 18 | 15.0% | +41.5% | +50.8% |
| Mar 2017 | Mar 2017 | 2 | 4.1% | +44.8% | +41.8% |
| May 2018 | May 2018 | 1 | 3.0% | +50.3% | +30.8% |
| Jun 2018 | Jul 2018 | 1 | 2.1% | +38.3% | +27.8% |
| Nov 2019 | Nov 2019 | 2 | 4.5% | +12.5% | +13.2% |
| Feb 2020 | May 2020 | 14 | 31.8% | +1.1% | +6.7% |
| Sep 2020 | Sep 2020 | 1 | 3.6% | +3.8% | +8.2% |
| Nov 2020 | Dec 2020 | 4 | 3.4% | +11.7% | +6.2% |
| Jan 2021 | May 2021 | 17 | 9.2% | +35.7% | +4.3% |
| May 2021 | Jun 2021 | 2 | 1.6% | +105.4% | +3.1% |
| Aug 2021 | Sep 2021 | 6 | 7.5% | +78.7% | +3.2% |
| Oct 2021 | Nov 2021 | 3 | 3.2% | +49.3% | +2.0% |
| Dec 2024 | Ongoing | 64+ | 51.5% | Ongoing | -46.3% |
| Average | 10 | — | +42.2% | — |
Frequently Asked Questions
Is AMPH below its 200-week moving average?
Yes. As of 2026-03-20, Amphastar Pharmaceuticals, Inc. (AMPH) is trading 47.9% below its 200-week moving average of $37.42. The current price is $19.50.
What is AMPH's 200-week moving average price?
Amphastar Pharmaceuticals, Inc.'s 200-week moving average is $37.42 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when AMPH drops below its 200-week moving average?
AMPH has crossed below its 200-week moving average 14 times in our data. On average, buying at that moment produced a one-year return of +42.2%. These dips have historically been decent entry points. These episodes lasted 10 weeks on average.
Is AMPH a good value right now?
Here's what our data says about AMPH as of 2026-03-20: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 36. Free cash flow yield is 9.1%. Return on equity is 12.9%. Price-to-book is 1.1x. This is not a buy or sell recommendation — always do your own research.
How does AMPH compare to the S&P 500?
Over the past 10.8 years, $100 invested in AMPH would have grown to $113, compared to $379 for the S&P 500. That's 1.1% annualized vs 13.1% for the index. AMPH has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20